Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 11/20 | 0.71 |
| ▸ | CA1 | P00915 | 10/20 | 0.71 |
| ▸ | CA9 | Q16790 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 2/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28228467 | 0.98 | LMNA (0.96) | LMNACA2CA1CA9MEN1 | |
| Methanesulfonamide SCHEMBL11803937 | 0.94 | LMNA (0.88) | LMNACA2CA1CA9MEN1 | |
| SCHEMBL3154840 | 0.93 | LMNA (0.88) | LMNACA2CA1CA9MEN1 | |
| SCHEMBL28384319 | 0.92 | LMNA (0.85) | LMNACA2CA1CA9MEN1 | |
| SCHEMBL9839080 | 0.91 | LMNA (0.82) | LMNACA2CA1CA9MEN1 | |
| Formic Acid SCHEMBL27594868 | 0.90 | LMNA (0.81) | LMNACA2CA1CA9MEN1 | |
| SCHEMBL3149535 | 0.84 | LMNA (0.71) | LMNACA2CA1CA9MEN1 | |
| SCHEMBL28746782 | 0.83 | LMNA (0.70) | LMNACA2CA1CA9MEN1 | |
| SCHEMBL10389380 | 0.83 | LMNA (0.69) | LMNACA2CA1CA9MEN1 | |
| SCHEMBL12283586 | 0.83 | LMNA (0.70) | LMNACA2CA1CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745119-A1 | ISOCYANATE COMPOSITION | Hanwha Solutions Corporation (KR) | 2026-05-20 | — | — | EP | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025128149-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-12 | — | — | US | claimed |
| CN-119528773-A | N-alkylation method of sulfonamide compound | 赣南医科大学 | 2025-02-28 | — | — | CN | claimed |
| WO-2025042219-A1 | ISOCYANATE COMPOSITION | 한화솔루션 주식회사 | 2025-02-27 | — | — | WO | claimed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | claimed |
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-118685793-A | Synthesis method of thio-N-heterocyclic compound | 南阳师范学院 | 2024-09-24 | — | — | CN | claimed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| EP-1069114-A2 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-17 | — | — | EP | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | claimed |
| EP-0757674-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1997-02-12 | — | — | EP | claimed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | claimed |
| WO-1995029159-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | claimed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | claimed |
| EP-0446748-A2 | Use of perylenedyes for the preparation of write, print or copying materials | RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) | 1991-09-18 | — | — | EP | claimed |
| US-4886813-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1989-12-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | FAP, FIBP, TPX2 | LMNA 1715/4885CA2 1845/4885CA1 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.